RVMD

LQAI · New entry · 1d

weight 0 → 0.330% (new)·stock up 22.3% in the 30 days before

Jul 7·entry $190.46·now $180.39Fresh

AIVL · Accumulation · 5d

The gradual accumulation of RVMD, with its weight in AIVL rising from 0.2853% to 0.2999% over the course of two weeks, reflects the AI manager’s nuanced assessment of the Health Care company. This steady, multi-day increase in allocation occurs even as RVMD trades near its 52-week high of $192.62 at $186.88, following 30-day and 90-day returns of over 20%. AIVL's AI, tasked with distinguishing genuine value from value traps within an already value-tilted universe by scoring fundamentals and valuation metrics, appears to be continually reaffirming RVMD's long-term value proposition. The incremental nature of these portfolio adjustments, rather than a sudden change, suggests the AI is consistently processing data and incrementally raising its conviction in RVMD's value, fitting the fund's periodic, not daily, rebalancing style.

weight 0.285% → 0.300% (+0.015 pp)·stock up 28.7% in the 30 days before

Jul 9·entry $191.13·now $180.39Fresh

AIVL · Accumulation · 6d

AIVL's gradual accumulation of RVMD, increasing its weight from 0.2786% to 0.2999% between late June and early July 2026, reflects the WisdomTree AI's assessment that RVMD's underlying fundamentals, such as its margins, return on capital, or free cash flow yield, continue to score highly within its pre-filtered US value-factor universe. This buying pattern occurred as RVMD traded near its 52-week high of $192.62, currently at $191.13, following a significant 30-day return of +24.9% and 90-day return of +23.4%. The AI, specifically designed to distinguish genuine value from value traps, likely identified sustained fundamental strength or attractive valuation metrics in RVMD that justify its inclusion and increased weighting, even with its stock price approaching the upper end of its annual range. The AI's analysis suggests that despite the upward price movement, RVMD's financial health, perhaps indicated by favorable debt levels, continues to align with AIVL's criteria for long-term value.

weight 0.279% → 0.300% (+0.021 pp)·stock up 27.2% in the 30 days before

Jul 8·entry $189.77·now $180.39Fresh

AIVL · Accumulation · 6d

WisdomTree's AIVL, which leverages AI to identify genuine value within its US value-factor universe by assessing fundamentals like margins and return on capital alongside valuation metrics such as P/E and FCF yield, initiated a consistent accumulation of Health Care sector company RVMD. Between June 24th and July 7th, 2026, the ETF’s weight in RVMD steadily increased from 0.2697% to 0.2972%. This gradual buying pattern occurred while RVMD’s price climbed to $189.77, placing it at 99% of its 52-week high of $192.62, and after the stock had already returned 22.5% over the prior 30, 90, and 365 days. The AI’s continued investment suggests its models perceived RVMD as holding strong underlying value, not merely a momentum play, thus avoiding the "value trap" designation even at elevated price levels relative to its historical range.

weight 0.270% → 0.297% (+0.028 pp)·stock up 22.3% in the 30 days before

Jul 7·entry $190.46·now $180.39Fresh

AIVL · Accumulation · 5d

AIVL demonstrated a gradual accumulation in RVMD, increasing its weight from 0.2704% to 0.2959% between late June and early July 2026. This measured buying aligns with WisdomTree's AIVL strategy, where its AI evaluates US value stocks like Health Care sector firm RVMD, seeking to distinguish genuine value from potential value traps within its pre-filtered universe. The AI's continuous assessment of RVMD's fundamental metrics, such as margins and return on capital, alongside valuation measures like P/E and FCF yield, likely indicated the stock presented a suitable allocation within its ~100-stock portfolio. The incremental additions, occurring within AIVL's periodic rebalance framework, suggest the AI consistently identified RVMD as an attractive opportunity to build its position at prevailing price levels.

weight 0.270% → 0.296% (+0.025 pp)·stock up 21.8% in the 30 days before

Jul 6·entry $189.99·now $180.39Fresh

AIVL · Accumulation · 5d

The gradual accumulation of Revolution Medicines Inc. (RVMD) in the AIVL portfolio during late June and early July, with its weighting increasing from 0.2617% to 0.2942%, reflects the fund's AI-driven strategy identifying a sustained investment opportunity. WisdomTree's AI, tasked with distinguishing genuine value from value traps within its pre-filtered US value-factor pool, likely assessed RVMD's fundamental metrics such as margins, return on capital, and debt alongside valuation metrics including P/E, P/B, and free cash flow yield. This measured increase suggests the AI algorithms determined the Health Care sector company met its criteria for inclusion and deserved a larger position within the portfolio of approximately 100 US value stocks. The periodic rebalancing of the fund allowed for this steady adjustment, as the AI signaled a consistent alignment of RVMD's profile with its value principles.

weight 0.262% → 0.294% (+0.033 pp)·stock up 25.1% in the 30 days before

Jul 2·entry $189.24·now $180.39Fresh

AIVL · Accumulation · 6d

The recorded change in AIVL's Revolution Medicines weighting exhibits a consistent, gradual accumulation, rising from 0.2591% to 0.2954% over a two-week period. This measured increase aligns with WisdomTree's AIVL strategy, where its AI periodically re-evaluates names within a pre-filtered US value-factor pool. For a Health Care company like RVMD, this suggests AIVL's AI, leveraging its analysis of fundamentals such as margins and return on capital alongside valuation metrics like P/E and FCF yield, is progressively distinguishing RVMD as a genuine value opportunity. The incremental adjustments indicate the AI's evolving conviction in RVMD's financial profile, signaling its growing comfort with the stock within its value-tilted universe.

weight 0.259% → 0.295% (+0.036 pp)·stock up 14.6% in the 30 days before

Jul 1·entry $187.51·now $180.39Fresh

AIVL · Accumulation · 6d

WisdomTree’s AIVL, a fund designed to distinguish genuine value from value traps within a pre-filtered US value-factor pool, has shown a consistent pattern of accumulation in Revolution Medicines Inc. The AI manager, which scores names based on fundamentals like return on capital and valuation metrics such as P/E, evidently identified evolving characteristics in RVMD that warranted a growing allocation. Reflecting this increasing conviction, RVMD's weight in the portfolio climbed from 0.2477% on June 16 to 0.2928% by June 30, a gradual adjustment aligned with the fund's periodic rebalancing schedule for its roughly 100 US value stocks.

weight 0.248% → 0.293% (+0.045 pp)·stock up 18.9% in the 30 days before

Jun 30·entry $187.28·now $180.39Fresh

AIVL · Accumulation · 6d

WisdomTree's AIVL, which scores stocks using fundamental and valuation metrics to distinguish genuine value from value traps within its pre-filtered US value-factor pool, has shown a sustained interest in RVMD. The AI's models appear to have progressively identified RVMD as a worthwhile holding, justifying increased allocation. This is evident in the gradual accumulation of its position, moving from 0.2454% on June 12th to 0.2853% by June 26th. Given the ETF's periodic rebalancing schedule and its portfolio of approximately 100 US value stocks, this steady accumulation indicates the AI's growing conviction in RVMD's financial profile.

weight 0.245% → 0.285% (+0.040 pp)·stock up 19.0% in the 30 days before

Jun 26·entry $182.08·now $180.39Fresh

AIVL · Accumulation · 6d

RVMD, a health care sector constituent, likely experienced a period where its share price traded near the lower end of its 52-week range. This valuation environment would have positioned the stock within AIVL's initial screen for US value factor candidates. WisdomTree's AI, specialized in distinguishing genuine value from value traps within this pre-filtered universe, proceeded to evaluate RVMD using its core fundamental and valuation metrics, scrutinizing aspects like margins, return on capital, debt, P/E, P/B, and FCF yield. The subsequent gradual accumulation, evidenced by AIVL increasing its RVMD weight from 0.2404% on June 11, 2026, to 0.2786% by June 25, 2026, signals the AI's assessment that RVMD represented a fundamentally sound holding at an appealing price, aligning with AIVL's specific value criteria.

weight 0.240% → 0.279% (+0.038 pp)·stock up 15.0% in the 30 days before

Jun 25·entry $178.17·now $180.39Fresh

AIVL · Accumulation · 6d

Leveraging its AI to differentiate genuine value from value traps within its pre-filtered US value-factor pool, WisdomTree's AIVL has been accumulating shares of Revolution Medicines Inc (RVMD). The fund's AI, which scores names based on fundamentals like margins and valuation metrics such as P/E, likely detected a sustained positive signal for RVMD. Operating within its portfolio of approximately 100 US value stocks and rebalancing periodically, AIVL's gradual increase in RVMD's weight from 0.2368% on June 10th to 0.2697% on June 24th illustrates this finding. This consistent adjustment suggests the AI perceives a strengthening of RVMD's value proposition, driving the measured accumulation.

weight 0.237% → 0.270% (+0.033 pp)

Jun 24·entry $169.77·now $180.39Drifting

AIVL · Accumulation · 6d

The weight in RVMD within AIVL displays a gradual, stepped accumulation, marked by several distinct percentage increases over a two-week period following an initial slight adjustment. This measured, non-daily cadence aligns directly with WisdomTree's AIVL methodology, which employs an AI to score names within a pre-filtered US value-factor pool and rebalances periodically, not continuously. The AI's analysis likely identified Revolution Medicines, a health care sector company, as a compelling value opportunity based on its fundamental metrics like margins, return on capital, or attractive valuation ratios such as P/E and FCF yield. This consistent, albeit discrete, increase in allocation suggests the algorithm is steadily building exposure to RVMD, confirming its assessment of genuine value versus a value trap at the prevailing market price range. Such a targeted expansion reflects the AI's specific mandate to distinguish and capitalize on long-term value within its universe.

weight 0.243% → 0.270% (+0.027 pp)

Jun 23·entry $169.51·now $180.39Drifting

AIVL · Accumulation · 5d

AIVL's AI, specifically designed to distinguish genuine value from value traps within a pre-filtered US value-factor universe, identified Revolution Medicines Inc for gradual accumulation. This activity is evident as RVMD's weight in the fund rose steadily from 0.2454% on June 5th to 0.2617% by June 22nd, reflecting the AI's positive assessment of the health care company's fundamentals. For a portfolio comprising approximately 100 US value stocks and rebalancing periodically, this consistent increase indicates the AI's continued conviction based on its detailed scoring of metrics such as return on capital or free cash flow yield.

weight 0.245% → 0.262% (+0.016 pp)

Jun 22·entry $165.81·now $180.39Drifting

AIVL · Weight increase · 4d

AIVL increased its allocation to Revolution Medicines Inc (RVMD) in a step-wise fashion from 0.2404% on June 11th to 0.2591% by June 18th. This gradual accumulation, occurring over several trading days despite AIVL’s periodic rebalancing schedule, suggests a sustained positive re-evaluation of the Health Care sector company by the fund’s AI. The AI, which scores names based on fundamentals like margins and return on capital, as well as valuation metrics such as free cash flow yield, appears to have found RVMD’s profile increasingly attractive. This consistent upward adjustment implies the AI’s model continuously distinguished RVMD as a strengthening genuine value proposition within its pre-filtered US value universe, leading to these incremental portfolio shifts.

weight 0.237% → 0.259% (+0.022 pp)

Jun 18·entry $162.99·now $180.39Chased

AIVL · Weight increase · 3d

WisdomTree's AIVL fund, which scores roughly 100 US value stocks using an AI focused on fundamentals like margins and valuation metrics such as FCF yield, increased its allocation to Revolution Medicines Inc. The AI's specific mandate is to distinguish genuine value from value traps within its predetermined value universe. This consecutive weight increase for RVMD, observed from 0.2368% on June 10th to 0.2477% by June 16th in the Health Care sector, suggests a re-evaluation of the company's profile. During a periodic rebalance, the AI's algorithm appears to have discerned a more favorable combination of fundamental health and attractive valuation, signaling RVMD as a solid value proposition.

weight 0.237% → 0.248% (+0.011 pp)

Jun 16·entry $156.58·now $180.39Chased

AIVL · Weight increase · 2d

AIVL's AI, tasked with identifying genuine value within its ~100 US value stocks, recently adjusted its allocation to Revolution Medicines Inc (RVMD) in the Health Care sector. Following an earlier period of declining weight, the system's re-assessment of RVMD's underlying fundamentals or valuation metrics, such as its return on capital or free cash flow yield, prompted a consecutive weight increase from 0.2368% on June 10th to 0.2454% by June 12th. This upward shift reflects the AI's periodic re-scoring process, designed to distinguish genuine value from potential value traps, rather than daily rebalancing, indicating RVMD's improved standing as a value opportunity within the fund's US value-factor pool.

weight 0.237% → 0.245% (+0.009 pp)

Jun 12·entry $153.87·now $180.39Chased

AIVL · New entry · 1d

Jun 1·entry $163.68·now $180.39Chased